Dapagliflozin plus methylcobalamin improved nerve function and glucose control in diabetic neuropathy.

Dapagliflozin is a selective inhibitor of sodium–glucose cotransporter 2 (SGLT2) that blocks glucose resorption in the proximal tubule of the kidney and promotes glucosuria. 11-13 Other SGLT2 ...

Dapagliflozin was stopped for reasons other than death in 249 patients and placebo was stopped in 258 patients (10.5% vs. 10.9%, P=0.71). At the last assessment, ...

Dapagliflozin propanediol is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. By reducing glucose reabsorption in the ...

Dapagliflozin produces a dose-dependent and sustained reduction in both fasting and postprandial serum glucose levels through increased urinary glucose excretion, ...

Dapagliflozin 10 mg also resulted in greater weight loss than did metformin (P < .0001). Events suggestive of genital infection were reported in 6.7%, 6.9%, ...

Dapagliflozin was well-tolerated, with no new safety issues identified. There were fewer serious adverse events in the dapagliflozin group vs. placebo (65 vs. 82). COVID-19 ‘not stable disease’ ...

Learn how SGLT2 inhibitor dapagliflozin improves MASH outcomes, with potential clinical use beyond diabetes care.

Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes. This 24-week, randomized ...

In adults with HF with mildly reduced or preserved ejection fraction, dapagliflozin significantly reduced risk for CV death and worsening HF compared with placebo, with no attenuation of treatment ...